Injectafer

Phase 3Small molecule

AAmerican Regent, Inc.

Injectafer is one of 13 small molecule programs targeting Intravenous. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IntravenousRecruiting

IntravenousPhase 3

Recruiting

Competition

Competitive Landscape

21 competitors in Intravenous

#DrugCompanyPhaseTrials

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

4 2

Ultram

WWim Janssens

Approved

1 3

Pitocin

RRetrophin

Phase 2

5 4

Magnesium SO4

HHospital de Base

Phase 3

1 5

Sodium Valproate

AstraZeneca

Phase 2

1 6

IV Thyroxin

RRambam Health Care Campus

Phase 3

1 7

Injectafer

AAmerican Regent, Inc.

Phase 3

1 8

Isordil

AstraZeneca

Preclinical

1 9

Esmeron

FFresenius Kabi USA, LLC

Preclinical

2 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia2 trials

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

Terminated·AAmerican Regent, Inc.·Phase 2·NCT02826681·70 enrolled

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

Completed·AAmerican Regent, Inc.·Phase 3·NCT02453334·244 enrolled

Inflammatory Bowel Disease1 trial

Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

Completed·AAmerican Regent, Inc.·Phase 4·NCT02086968·198 enrolled

Treatment1 trial

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

Completed·AAmerican Regent, Inc.·Phase 3·NCT02397057·209 enrolled

Intravenous1 trial

Intravenous Iron Effects on Performance at High Altitude

Recruiting·—·Phase 4·NCT06686693·24 enrolled

Fibromyalgia1 trial

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Completed·AAmerican Regent, Inc.·Phase 2·NCT02409459·81 enrolled

1 more indication

Hepcidin1 trial

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

Completed·AAmerican Regent, Inc.·Phase 4·NCT01950247·1,025 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Injectafer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Injectafer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Injectafer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — American Regent, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAmerican Regent, Inc.

Injectafer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia2 trials

Inflammatory Bowel Disease1 trial

Treatment1 trial

Intravenous1 trial

Fibromyalgia1 trial

Hepcidin1 trial

References

Drug Info

Quick Facts

Related News